TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults with biopsy proven and serology-confirmed celiac disease on a gluten-free diet for at least 12 months~* measurable serology at screening~* CeD GSRS score of ≥ 2.0 prior to randomization~* experiencing symptoms (ie, diarrhea, abdominal pain, bloating, nausea, or stomachache)~* willing to maintain current diet gluten-free diet throughout the duration of the study.~Exclusion Criteria:~* refractory celiac disease or severe complications of celiac disease (eg, EATL, ulcerative jejunitis, perforation, etc.)~* chronic active GI disease other than celiac disease~* diabetes (Type 1 or 2) or other autoimmune disease that might interfere with the conduct of the study~* hemoglobin value \< 8.5 g/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Larazotide Acetate 0.5 mg (Type: EXPERIMENTAL): larazotide acetate 0.5 mg capsules TID
- Larazotide Acetate 1 mg (Type: EXPERIMENTAL): larazotide acetate 1 mg capsules TID
- Larazotide Acetate 2 mg (Type: EXPERIMENTAL): larazotide acetate 2 mg capsules TID
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsules TID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* HCV treatment-naive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any interferon (IFN), RBV, or other approved or experimental HCV-specific direct-acting antiviral agent, or HCV treatment-experienced (HCV genotype 1, 2, 3, or 6 only) with medical records that include sufficient detail of prior treatment with IFN to allow for categorization of prior response as either IFN Intolerant, non-responder, or experiences viral breakthrough or relapse~* HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy~Key Exclusion Criteria:~* Current or prior history of any clinically-significant illness (other than HCV)~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non-HCV etiology~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+RBV+PEG 12 weeks (Type: EXPERIMENTAL): Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
- Sofosbuvir+RBV 12 weeks (Type: EXPERIMENTAL): Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
- Sofosbuvir+RBV 16 weeks (Type: EXPERIMENTAL): Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
- Sofosbuvir+RBV 24 Weeks (Type: EXPERIMENTAL): Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent~2. Male or female patients, aged ≥40 years~3. Patient undergoing phacoemulsification~4. Corneal thickness between 450 μm and 600 μm as measured by means of pachymetry~5. Corneal integrity confirmed by means of fluorescein test~6. Adequate pupil dilation assessed at screening~7. Female patients of childbearing potential must have a negative pregnancy test~8. Ability to fully understand all study procedures~Exclusion Criteria:~1. Corneal epithelium integrity not confirmed by fluorescein test~2. History of corneal disease or dystrophy~3. History of ocular trauma with corneal damage~4. History of acute ocular inflammation (including uveitis) in the 6 months prior to screening~5. Previous ocular surgery (including laser treatment)~6. Glaucoma~7. Treatment with an ophthalmic investigational drug in the 3 months prior to screening~8. Treatment with any topical ocular drug within 12 hours before start of cataract surgery other than study drugs and instillation of topical anaesthetic within 10 minutes before start of surgery~9. Treatment with any topical steroid or antibiotic drug in the 7 days prior to cataract surgery~10. Treatment with any systemic steroid or antibiotic drug in the 7 days prior to cataract surgery~11. Known hypersensitivity to levofloxacin, other fluoroquinolones or dexamethasone~12. Pregnant or lactating women~13. Patients who have received any investigational drug during the preceding 30 days or 5 times the plasma half-life, or who have previously participated in this trial

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levofloxacin + Dexamethasone (Type: EXPERIMENTAL): Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery.
- Levofloxacin (Type: ACTIVE_COMPARATOR): Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery.
- Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has pathologically documented unresectable, recurrent, or metastatic colorectal adenocarcinoma (until sponsor's notification to the study sites, subject must be a RAS/BRAF wild-type cancer)~* Has received at least 2 prior regimens of standard treatment~* Has measurable disease assessed by the investigator based on RECIST version 1.1.~* Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1~Exclusion Criteria:~* Has a medical history of myocardial infarction within 6 months, symptomatic congestive heart failure~* Has a medical history of clinically significant lung disease~* Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-8201a Cohort A (Type: EXPERIMENTAL): Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
- DS-8201a Cohort B (Type: EXPERIMENTAL): Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
- DS-8201a Cohort C (Type: EXPERIMENTAL): Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Oral Premalignant Lesions With 5-ALA PDT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least one grossly visible premalignant lesion (i.e. leukoplakia or erythroplakia) in the oral cavity or oropharynx, with a confirmed diagnosis of leukoplakia with or without dysplasia,measuring ≥ 10 mm in diameter.~* Informed of alternative treatment methods including watchful waiting, laser ablation, or surgical resection.~* Eligible for long-term follow-up for at least one year and be able to tolerate biopsies.~* Subject has signed an informed consent.~* Subject is between the ages of 18 - 80 years of age.~* Male or Female~* Zubrod performance status of 0 or 1 at screening. See Appendix A~Exclusion Criteria:~* Known sensitivity to porphyrins or photoactive medications - See Appendix B~* Invasive carcinoma of the lesion as demonstrated by biopsy.~* Subjects with inherited or acquired blood clotting defects~* Women who are breast feeding, have a positive (+) urine pregnancy test, or refuse to use 2 effective means of contraception during drug exposure and up to 48 hours after.~* Subjects with porphyria~* Life expectancy less than 12 months~* Inability or unwillingness of subject to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1 light dose escalation (Type: EXPERIMENTAL): During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2.
- Phase 2 - Treatment efficacy of PDT (Type: EXPERIMENTAL): Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* A diagnosis of chronic rheumatologic conditions or inflammatory bowel disease or Duchenne muscular dystrophy requiring systemic glucocorticoids (i.v. or oral) within 12 months prior to screening~* Lumbar Spine BMDZ-score of -0.5 or worse~* Evidence of at least at least 1 vertebral compression fracture of Genant Grade 1 or higher (or radiographic signs of vertebral fracture) within 1 month from Screening visit OR One or more, low-trauma, lower extremity long-bone fracture which occurred sometime within the 2 years PRECEDING enrollment in the study OR Two or more, low-trauma, upper extremity long-bone fractures which occurred sometime within the 2 years PRECEDING enrollment in the study~* Consent/assent to study participation~Key Exclusion Criteria:~* History of primary bone disease (OI, Idiopathic Juvenile Osteoporosis, Rickets/Osteomalacia)~* Any medical condition that might have interfered with the evaluation of lumbar spine BMD, such as severe scoliosis or spinal fusion. Patients with less than 3 evaluable vertebrae by Dual Energy X-ray Absorptiometry (DXA) evaluation in the region of interest lumbar 1 (L1) to lumbar 4 (L4),~* Hypocalcemia and hypophosphatemia~* Serum 25-hydroxy vitamin D concentrations of \<20 ng/mL or \<50 nmol/L~* estimated glomerular filtration rate (GFR) \<60 mL/min/1.73 m2~* serum creatinine increase between Visit 1 and Visit 2 \>0.5 mg/dL (44.2 μmol/L)~* Uncontrolled symptoms of cardiac failure or arrhythmia~* Any prior use of bisphosphonates, or high dose sodium fluoride

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: EXPERIMENTAL): Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
- Placebo (Type: PLACEBO_COMPARATOR): Twice yearly i.v of infusion of Placebo (similar dosing as active drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering as least 10%of body surface area~* a Psoriasis Area and Severity Index (PASI) score of 12 and are considered to be candidates for systemic or light therapy~* No evidence of active or latent tuberculosis~Exclusion Criteria:~* Non-plaque or drug induced forms of psoriasis~* cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)~* any uncontrolled significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment 10 mg BID (Type: EXPERIMENTAL): None
- ActiveTreatment 5 mg BID (Type: EXPERIMENTAL): None
- Placebo Treatment (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older~* Viral load \< 50,000 copies/mL and CD4+ T cell count \>= 200/uL within 6 months before study vaccination~* Receiving stable highly active antiretroviral therapy (HAART) or not currently receiving any antiretroviral therapy~* No previous vaccination with a pneumococcal vaccine~* Subject or parent/legal guardian able to complete an electronic diary~Exclusion Criteria:~* Acquired immune deficiency syndrome (AIDS) at time of enrollment~* Current illicit substance and/or alcohol abuse~* History of active chronic viral hepatitis~* Previous anaphylactic reaction to a vaccine or vaccine-related component~* Serious chronic disorders including metastatic malignancy and end-stage renal disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of HIV/Sexually Transmitted Infection Training for Physicians in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria for Patient Participants:~* Tests positive for the presence of gonorrhea or chlamydia~* Plans on living in current community for at least 9 months after study entry~* Willing to provide contact information for 9-month follow-up~Inclusion Criteria for County Level Physician Participants:~* Specializes in STI, obstetrics/gynecology, urology, infectious disease, or HIV care~* Minimum of 3 years of clinical experience as verified by practice supervisor~* Sees HIV/STI and related patients in his/her practice~* Willing to participate for the entire duration of the training, including secondary training stage~Inclusion Criteria for Township Level Physicians Participants:~* Minimum of 3 years of clinical experience as verified by practice supervisor~* Works in a high service volume area (among the top one-third within his/her host township health center)~* Sees HIV/STI and related patients in his/her practice~* Willing to participate for the entire duration of the training, including secondary training stage~Exclusion Criteria for All Participants:~* Presence of an obvious psychological/psychiatric disorder that would invalidate the informed consent process or otherwise contraindicate participation in the assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Physicians of county level will receive Ai Shi Zi training provided by experts in the fields of HIV/STIs, behavioral counseling, and stigma reduction.
- 2 (Type: EXPERIMENTAL): Physicians of township level will receive Ai Shi Zhi training provided by the county level physicians.
- 3 (Type: EXPERIMENTAL): HIV/STI patients will receive standard of care and specialized care from physician participants trained in Ai Shi Zi.
- 4 (Type: NO_INTERVENTION): Physicians of county level who will not participate in Ai Shi Zi training
- 5 (Type: NO_INTERVENTION): Physicians of township level who will not participate in Ai Shi Zi training
- 6 (Type: SHAM_COMPARATOR): HIV/STI patients who will receive standard care only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chinese ethnicity defined as having both parents and 4 grandparents who are Chinese~* Have a normal Body size and weigh at least 50 kg~Exclusion Criteria:~* History of diseases or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs determined by the investigator~* Current and/or past history of intolerance or hypersensitivity to drugs with a similar chemical structure or mechanism of action to AZD6140 or any ingredient in its formulation~* Symptoms of any clinically significant illness within 2 weeks of screening~* A personal or family history of bleeding diatheses or a reasonable suspicion of vascular abnormalities including aneurysms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent and aged between 18 and 75 years of age.~* Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.~* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.~* Able and agrees to remain off prior antipsychotic medication for the duration of study.~* Good physical health on the basis of medical history, physical examination, and laboratory screening.~* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.~Exclusion Criteria:~* Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.~* Any chronic organic disease of the CNS (other than schizophrenia).~* Used investigational compound within 30 days.~* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone 80mg (Type: EXPERIMENTAL): None
- Lurasidone 160mg (Type: EXPERIMENTAL): None
- Quetiapine XR (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Deficiency in Adults (GHDA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diagnosed GHD~* If the subject has a history of treatment of treatment for a tumour of pituitary or peripheral site, two years or more must have passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be excluded~* Appropriate replacement therapy has been administered for more than 24 weeks for the treatment of other pituitary hormone deficiencies~Exclusion Criteria:~* Subject with a history of acromegaly~* Subject with diabetes mellitus~* Subject suffering from malignancy~* Several medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete